Financial StabilityAs of Sep 2025, SERA had $102.4M cash to fund operations through 2028.
Product InnovationPreTRM is the first predictive blood test to assess preterm birth risk in asymptomatic women, and it has demonstrated meaningful improvements in neonatal outcomes.
Strategic PartnershipsSera’s Elevance Health partnership involved collaborating on the PRIME trial and a $20M pre-purchase of PreTRM tests.